Anthropic Launches Claude Science, Enters Drug Discovery
2 min readAnthropic is not just building AI for scientists anymore. It wants to discover drugs itself. On June 30, 2026, the company behind Claude gathered pharmaceutical executives, biotech founders, and academic researchers in San Francisco to launch Claude Science, a research workbench, and to reveal that it is starting its own internal drug discovery program.
From Chatbot to Lab Bench
AI has been creeping into pharmaceutical research for years, from protein folding to molecule screening, but the tools have stayed scattered across dozens of separate databases and programs. Anthropic’s pitch is consolidation. Claude Science bundles more than 60 built-in scientific capabilities spanning genomics, structural biology, proteomics, and cheminformatics into a single environment, so a researcher can design a CRISPR screening experiment, analyze single-cell RNA sequencing data, and generate 3D protein structures without stitching together a patchwork of software.
What Claude Science Does
The workbench is available in beta to Pro, Max, Team, and Enterprise users, with early customers including Novo Nordisk and the Allen Institute. Researchers can also produce chemistry drawings and genome browser tracks directly in the tool. More striking is Anthropic’s decision to run its own drug discovery program rather than simply sell software, as CNBC reported. The company says it will focus on neglected diseases that traditional drugmakers have long avoided as commercially unattractive, using the effort to learn firsthand what models and features researchers actually need.
To seed adoption, Anthropic is offering up to $30,000 in credits across as many as 50 research projects. Applications close July 15, with recipients named by the end of the month.
Why It Matters
The launch drops Anthropic into a three-way race with Google and OpenAI, both of which have their own scientific AI ambitions. It also reads as a business move: a concrete B2B revenue line in healthcare, a lucrative and sticky market, ahead of Anthropic’s expected IPO. For patients, the more meaningful question is whether an AI company chasing neglected diseases can actually push a candidate toward the clinic.
Selling software is one thing. Discovering a working drug is a far harder, slower, and more expensive challenge. Whether Claude Science delivers real medicines or mostly faster analysis will take years to judge, but Anthropic has now put its own research on the line to find out.